Taxotere, Docetaxel Newswire (Page 2)

Taxotere, Docetaxel Newswire (Page 2)

Comprehensive Real-Time News Feed for Taxotere, Docetaxel (generic). (Page 2)

Results 21 - 40 of 584 in Taxotere, Docetaxel (generic)

  1. Endocyte Inc. (ECYT) Upgraded by Zacks Investment Research to "Hold"Read the original story w/Photo

    Wednesday Aug 17 | AmericanBankingNews.com

    According to Zacks, "Endocyte reported a wider-than-expected loss in the second-quarter of 2016. Moreover, estimates have come down post the second-quarter numbers.

    Comment?

  2. Zacks Investment Research Upgrades Endocyte Inc. (ECYT) to HoldRead the original story w/Photo

    Wednesday Aug 17 | AmericanBankingNews.com

    According to Zacks, "Endocyte reported a wider-than-expected loss in the second-quarter of 2016. Moreover, estimates have come down post the second-quarter numbers.

    Comment?

  3. Eagle Pharmaceuticals Inc. (EGRX) Shares Down 1.2%Read the original story w/Photo

    Wednesday Aug 17 | Daily Political

    Eagle Pharmaceuticals Inc. 's share price traded down 1.2% during mid-day trading on Monday . The stock traded as low as $60.14 and last traded at $61.33, with a volume of 176,639 shares changing hands.

    Comment?

  4. Eagle Pharmaceuticals Inc. (EGRX) Trading Up 1.9% on Analyst UpgradeRead the original story w/Photo

    Wednesday Aug 17 | Daily Political

    Eagle Pharmaceuticals Inc. was up 1.9% on Tuesday after Mizuho raised their price target on the stock from $47.00 to $65.00. Mizuho currently has a neutral rating on the stock.

    Comment?

  5. Custirsen Fails to Improve Prostate Cancer in Phase 3 TrialRead the original story

    Tuesday Aug 16 | P&T Community

    OncoGenex Pharmaceuticals has announced results from the final analysis of its phase 3 AFFINITY study of custirsen in men with metastatic castrate-resistant prostate cancer whose disease has progressed after treatment with docetaxel. The international, randomized, open-label trial did not meet its primary endpoint of demonstrating a statistically significant improvement in overall survival for patients treated with custirsen in combination with cabazitaxel/prednisone compared with cabazitaxel/prednisone alone.

    Comment?

  6. Eagle Pharmaceuticals Inc. (EGRX) Trading Up 1.9% Following Analyst UpgradeRead the original story w/Photo

    Tuesday Aug 16 | AmericanBankingNews.com

    Eagle Pharmaceuticals Inc. traded up 1.9% during mid-day trading on Tuesday after Mizuho raised their price target on the stock from $47.00 to $65.00. Mizuho currently has a neutral rating on the stock.

    Comment?

  7. OncoGenex seeks strategic alternatives after drug study failsRead the original story w/Photo

    Tuesday Aug 16 | Reuters

    OncoGenex Pharmaceuticals Inc said it was exploring strategic alternatives after its experimental drug failed to show survival benefit in a late-stage study in patients with advanced prostate cancer. The drug, custirsen, did not show a statistically significant improvement in overall survival in patients with metastatic castrate-resistant prostate cancer whose disease progressed despite treatment with the chemotherapeutic agent, docetaxel.

    Comment?

  8. OncoGenex's custirsen flunks late-stage study in prostate cancer; shares slump 34% premarketRead the original story w/Photo

    Tuesday Aug 16 | Seeking Alpha

    Thinly traded nano cap OncoGenex is down 34% premarket on light volume in response to its announcement that its Phase 3 clinical trial, AFFINITY , assessing lead product candidate custirsen, in combination with cabazitaxel/prednisone, for the treatment of metastatic castration-resistant prostate cancer that has progressed after treatment with docetaxel failed to achieve its primary endpoint of a statistically valid improvement in overall survival compared to cabazitaxel/prednisone alone. Complete data will be presented the the European Society for Medical Oncology Annual Congress in Copenhagen in early October.

    Comment?

  9. Eagle Pharmaceuticals Inc. (EGRX) Price Target Raised to $65.00 at MizuhoRead the original story w/Photo

    Tuesday Aug 16 | AmericanBankingNews.com

    The firm currently has a "neutral" rating on the specialty pharmaceutical company's stock. Mizuho's price target would suggest a potential upside of 7.15% from the company's previous close.

    Comment?

  10. OncoGenex Hires Advisor, Seeks Strategic Alternatives After Cancer Drug Custirsen Study FailsRead the original story

    Monday Aug 15 | BioSpace

    The trial did not meet the primary endpoint of demonstrating a statistically significant improvement in overall survival for patients treated with custirsen in combination with cabazitaxel/prednisone compared to cabazitaxel/prednisone alone. The adverse events were consistent with those observed in previous trials of custirsen in metastatic CRPC.

    Comment?

  11. Eagle Pharmaceuticals Inc. (EGRX) Trading Down 1.2%Read the original story w/Photo

    Monday Aug 15 | Daily Political

    Eagle Pharmaceuticals Inc. shares fell 1.2% on Monday . The company traded as low as $60.14 and last traded at $61.33, with a volume of 176,639 shares changing hands.

    Comment?

  12. Zacks Investment Research Lowers Endocyte Inc. (ECYT) to SellRead the original story w/Photo

    Monday Aug 15 | Daily Political

    According to Zacks, "Endocyte reported a wider-than-expected loss in the second-quarter of 2016. With no approved product in its portfolio at the moment, Endocyte has to depend heavily on its partners for top-line growth.

    Comment?

  13. Eagle Pharmaceuticals Inc. (EGRX) Upgraded to Hold by TheStreetRead the original story w/Photo

    Monday Aug 15 | Daily Political

    Eagle Pharmaceuticals opened at 62.05 on Tuesday. Eagle Pharmaceuticals has a 12-month low of $33.02 and a 12-month high of $102.48.

    Comment?

  14. BeyondSpring Pharmaceuticals Announces First Patient Enrolled In...Read the original story

    Sunday Aug 14 | BioSpace

    Shanghai Chest Hospital has extensive experience conducting global Phase 3 trials in non-small cell lung cancer and has participated in trials with drugs approved by the U.S. FDA. Plinabulin is in a global Phase 3 trial in 2nd and 3rd line non-small cell lung cancer in combination with docetaxel .

    Comment?

  15. Prostate cancer patients in Wales set to benefit from earlier access to vital form of chemotherapyRead the original story w/Photo

    Sunday Aug 14 | IcNetwork

    Men in Wales newly diagnosed with advanced prostate cancer will now be offered earlier access to a vital form of chemotherapy, it has been revealed. Prostate Cancer UK has confirmed that docetaxel chemotherapy will now be made available sooner alongside hormone therapy to eligible patients.

    Comment?

  16. Q3 2016 Earnings Forecast for Eagle Pharmaceuticals Inc. (EGRX) Issued By William BlairRead the original story w/Photo

    Saturday Aug 13 | Daily Political

    Eagle Pharmaceuticals Inc. - Research analysts at William Blair lifted their Q3 2016 earnings estimates for Eagle Pharmaceuticals in a research report issued on Tuesday. William Blair analyst T. Lugo now forecasts that the firm will post earnings of $0.99 per share for the quarter, up from their prior forecast of $0.93.

    Comment?

  17. Bristol Myers: Science Trumps The HeadlinesRead the original story w/Photo

    Friday Aug 12 | Seeking Alpha

    Since last Friday, Bristol-Myers Squibb has dropped nearly 19% after reporting that Opdivo failed to meet its primary endpoint of progression-free survival in patients with previously untreated advanced NSCLC. Contrary to my peers, I see this drop in Bristol-Myer's as a buying opportunity and I rate BMS as a strong buy at these levels.

    Comment?

  18. Eagle Pharmaceuticals Inc. (EGRX) Expected to Earn FY2017 Earnings of $4.92 Per ShareRead the original story w/Photo

    Thursday Aug 11 | AmericanBankingNews.com

    Eagle Pharmaceuticals Inc. - Research analysts at William Blair dropped their FY2017 earnings per share estimates for shares of Eagle Pharmaceuticals in a report issued on Tuesday. William Blair analyst T. Lugo now forecasts that the firm will earn $4.92 per share for the year, down from their previous estimate of $5.13.

    Comment?

  19. Eagle Pharmaceuticals Inc. (EGRX) Announces Earnings ResultsRead the original story w/Photo

    Thursday Aug 11 | Daily Political

    Eagle Pharmaceuticals Inc. issued its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.71 by $0.09.

    Comment?

  20. Human SRMAtlas: A Resource of Targeted Assays to Quantify the Complete Human Proteome.Read the original story

    Monday Aug 8 | CiteULike

    The ability to reliably and reproducibly measure any protein of the human proteome in any tissue or cell type would be transformative for understanding systems-level properties as well as specific pathways in physiology and disease. Here, we describe the generation and verification of a compendium of highly specific assays that enable quantification of 99.7% of the 20,277 annotated human proteins by the widely accessible, sensitive, and robust targeted mass spectrometric method selected reaction monitoring, SRM.

    Comment?